These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29872475)

  • 1. Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes.
    A Oliveros R; V Pham S; R Bailey S; J Chilton R
    Eur Endocrinol; 2014 Aug; 10(2):117-123. PubMed ID: 29872475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Neumiller JJ
    Drugs Context; 2014; 3():212262. PubMed ID: 24991224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
    Seufert J
    Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes.
    Peene B; Benhalima K
    Ther Adv Endocrinol Metab; 2014 Oct; 5(5):124-36. PubMed ID: 25419452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes.
    Mikhail N
    World J Diabetes; 2014 Dec; 5(6):854-9. PubMed ID: 25512787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.
    Mascolo A; Di Napoli R; Balzano N; Cappetta D; Urbanek K; De Angelis A; Scisciola L; Di Meo I; Sullo MG; Rafaniello C; Sportiello L
    Front Cardiovasc Med; 2022; 9():1010693. PubMed ID: 36211584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors in the treatment of type 2 diabetes.
    Hasan FM; Alsahli M; Gerich JE
    Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
    d'Emden M; Amerena J; Deed G; Pollock C; Cooper ME
    Diabetes Res Clin Pract; 2018 Feb; 136():23-31. PubMed ID: 29196150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Lopez JM; Macomson B; Ektare V; Patel D; Botteman M
    Am Health Drug Benefits; 2015 Sep; 8(6):309-18. PubMed ID: 26557225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.
    Clar C; Gill JA; Court R; Waugh N
    BMJ Open; 2012; 2(5):. PubMed ID: 23087012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.